Edgewise Therapeutics has announced positive 2-month interim results from the ARCH open-label study of EDG-5506 in adults with Becker muscular dystrophy.

Results showed that EDG-5506 treatment significantly lowered muscle damage biomarkers in adults with Becker. The patients were more active during two months of dosing with EDG-5506 relative to activity measured in the individuals who participated in Phase 1, and EDG-5506 was well tolerated with no serious adverse events observed. EDG-5506 also has an application for patients with DMD. The safety profile observed supports dose escalation to the next dose level for all in the trial. We are pleased with these results and our continued progress.

“The magnitude of reduction in biomarkers of muscle damage in adults with BMD is consistent with our observations in the Phase 1b trial. We’re encouraged by the decrease in biomarkers, particularly in the context of the increased activity observed in BMD patients treated with EDG-5506.”

Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Edgewise

“I want to express my deepest appreciation to the individuals with BMD who are participating in the EDG-5506 clinical trials,” added Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. “These interim 2-month ARCH data are promising, and we look forward to sharing further updates after patients have been dosed for six months.”

Click the link below to read the full press release.